- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.39 Å
- Oligo State
- homo-hexamer
- Ligands
- 6 x 9VI: N-[(1S)-1-(3-{4-chloro-3-[(methanesulfonyl)amino]-1-methyl-1H-indazol-7-yl}-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl]-2-[3-(trifluoromethyl)-6,7-dihydro-1H-indazol-1-yl]acetamide(Non-covalent)
- 24 x IOD: IODIDE ION(Non-functional Binders)
IOD.2: 1 residues within 4Å:- Chain E: P.38
Ligand excluded by PLIPIOD.3: 4 residues within 4Å:- Chain A: G.156, P.157, K.158, E.159
Ligand excluded by PLIPIOD.4: 4 residues within 4Å:- Chain A: R.162, M.215, Q.219
- Chain F: M.144
Ligand excluded by PLIPIOD.5: 1 residues within 4Å:- Chain A: P.17
Ligand excluded by PLIPIOD.14: 1 residues within 4Å:- Chain F: P.38
Ligand excluded by PLIPIOD.15: 4 residues within 4Å:- Chain B: G.156, P.157, K.158, E.159
Ligand excluded by PLIPIOD.16: 4 residues within 4Å:- Chain B: R.162, M.215, Q.219
- Chain D: M.144
Ligand excluded by PLIPIOD.17: 1 residues within 4Å:- Chain B: P.17
Ligand excluded by PLIPIOD.26: 1 residues within 4Å:- Chain D: P.38
Ligand excluded by PLIPIOD.27: 4 residues within 4Å:- Chain C: G.156, P.157, K.158, E.159
Ligand excluded by PLIPIOD.28: 4 residues within 4Å:- Chain C: R.162, M.215, Q.219
- Chain E: M.144
Ligand excluded by PLIPIOD.29: 1 residues within 4Å:- Chain C: P.17
Ligand excluded by PLIPIOD.38: 1 residues within 4Å:- Chain B: P.38
Ligand excluded by PLIPIOD.39: 4 residues within 4Å:- Chain D: G.156, P.157, K.158, E.159
Ligand excluded by PLIPIOD.40: 4 residues within 4Å:- Chain C: M.144
- Chain D: R.162, M.215, Q.219
Ligand excluded by PLIPIOD.41: 1 residues within 4Å:- Chain D: P.17
Ligand excluded by PLIPIOD.50: 1 residues within 4Å:- Chain C: P.38
Ligand excluded by PLIPIOD.51: 4 residues within 4Å:- Chain E: G.156, P.157, K.158, E.159
Ligand excluded by PLIPIOD.52: 4 residues within 4Å:- Chain A: M.144
- Chain E: R.162, M.215, Q.219
Ligand excluded by PLIPIOD.53: 1 residues within 4Å:- Chain E: P.17
Ligand excluded by PLIPIOD.62: 1 residues within 4Å:- Chain A: P.38
Ligand excluded by PLIPIOD.63: 4 residues within 4Å:- Chain F: G.156, P.157, K.158, E.159
Ligand excluded by PLIPIOD.64: 4 residues within 4Å:- Chain B: M.144
- Chain F: R.162, M.215, Q.219
Ligand excluded by PLIPIOD.65: 1 residues within 4Å:- Chain F: P.17
Ligand excluded by PLIP- 42 x CL: CHLORIDE ION(Non-functional Binders)
CL.6: 5 residues within 4Å:- Chain A: G.60, G.61
- Chain E: E.35, K.170, R.173
Ligand excluded by PLIPCL.7: 3 residues within 4Å:- Chain A: P.160, F.161, R.162
Ligand excluded by PLIPCL.8: 2 residues within 4Å:- Chain A: I.153, R.167
Ligand excluded by PLIPCL.9: 2 residues within 4Å:- Chain A: T.148, D.152
Ligand excluded by PLIPCL.10: 3 residues within 4Å:- Chain A: E.28, G.60, H.62
Ligand excluded by PLIPCL.11: 1 residues within 4Å:- Chain A: I.124
Ligand excluded by PLIPCL.12: 3 residues within 4Å:- Chain A: S.16, P.17, R.18
Ligand excluded by PLIPCL.18: 5 residues within 4Å:- Chain B: G.60, G.61
- Chain F: E.35, K.170, R.173
Ligand excluded by PLIPCL.19: 3 residues within 4Å:- Chain B: P.160, F.161, R.162
Ligand excluded by PLIPCL.20: 2 residues within 4Å:- Chain B: I.153, R.167
Ligand excluded by PLIPCL.21: 2 residues within 4Å:- Chain B: T.148, D.152
Ligand excluded by PLIPCL.22: 3 residues within 4Å:- Chain B: E.28, G.60, H.62
Ligand excluded by PLIPCL.23: 1 residues within 4Å:- Chain B: I.124
Ligand excluded by PLIPCL.24: 3 residues within 4Å:- Chain B: S.16, P.17, R.18
Ligand excluded by PLIPCL.30: 5 residues within 4Å:- Chain C: G.60, G.61
- Chain D: E.35, K.170, R.173
Ligand excluded by PLIPCL.31: 3 residues within 4Å:- Chain C: P.160, F.161, R.162
Ligand excluded by PLIPCL.32: 2 residues within 4Å:- Chain C: I.153, R.167
Ligand excluded by PLIPCL.33: 2 residues within 4Å:- Chain C: T.148, D.152
Ligand excluded by PLIPCL.34: 3 residues within 4Å:- Chain C: E.28, G.60, H.62
Ligand excluded by PLIPCL.35: 1 residues within 4Å:- Chain C: I.124
Ligand excluded by PLIPCL.36: 3 residues within 4Å:- Chain C: S.16, P.17, R.18
Ligand excluded by PLIPCL.42: 5 residues within 4Å:- Chain B: E.35, K.170, R.173
- Chain D: G.60, G.61
Ligand excluded by PLIPCL.43: 3 residues within 4Å:- Chain D: P.160, F.161, R.162
Ligand excluded by PLIPCL.44: 2 residues within 4Å:- Chain D: I.153, R.167
Ligand excluded by PLIPCL.45: 2 residues within 4Å:- Chain D: T.148, D.152
Ligand excluded by PLIPCL.46: 3 residues within 4Å:- Chain D: E.28, G.60, H.62
Ligand excluded by PLIPCL.47: 1 residues within 4Å:- Chain D: I.124
Ligand excluded by PLIPCL.48: 3 residues within 4Å:- Chain D: S.16, P.17, R.18
Ligand excluded by PLIPCL.54: 5 residues within 4Å:- Chain C: E.35, K.170, R.173
- Chain E: G.60, G.61
Ligand excluded by PLIPCL.55: 3 residues within 4Å:- Chain E: P.160, F.161, R.162
Ligand excluded by PLIPCL.56: 2 residues within 4Å:- Chain E: I.153, R.167
Ligand excluded by PLIPCL.57: 2 residues within 4Å:- Chain E: T.148, D.152
Ligand excluded by PLIPCL.58: 3 residues within 4Å:- Chain E: E.28, G.60, H.62
Ligand excluded by PLIPCL.59: 1 residues within 4Å:- Chain E: I.124
Ligand excluded by PLIPCL.60: 3 residues within 4Å:- Chain E: S.16, P.17, R.18
Ligand excluded by PLIPCL.66: 5 residues within 4Å:- Chain A: E.35, K.170, R.173
- Chain F: G.60, G.61
Ligand excluded by PLIPCL.67: 3 residues within 4Å:- Chain F: P.160, F.161, R.162
Ligand excluded by PLIPCL.68: 2 residues within 4Å:- Chain F: I.153, R.167
Ligand excluded by PLIPCL.69: 2 residues within 4Å:- Chain F: T.148, D.152
Ligand excluded by PLIPCL.70: 3 residues within 4Å:- Chain F: E.28, G.60, H.62
Ligand excluded by PLIPCL.71: 1 residues within 4Å:- Chain F: I.124
Ligand excluded by PLIPCL.72: 3 residues within 4Å:- Chain F: S.16, P.17, R.18
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Adu-Ampratwum, D. et al., Disulfide stabilized HIV-1 CA hexamer in complex with capsid inhibitor N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide. To Be Published
- Release Date
- 2022-10-05
- Peptides
- Capsid protein p24: ABCDEF
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
AC
AD
AE
AF
A
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.39 Å
- Oligo State
- homo-hexamer
- Ligands
- 6 x 9VI: N-[(1S)-1-(3-{4-chloro-3-[(methanesulfonyl)amino]-1-methyl-1H-indazol-7-yl}-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl]-2-[3-(trifluoromethyl)-6,7-dihydro-1H-indazol-1-yl]acetamide(Non-covalent)
- 24 x IOD: IODIDE ION(Non-functional Binders)
- 42 x CL: CHLORIDE ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Adu-Ampratwum, D. et al., Disulfide stabilized HIV-1 CA hexamer in complex with capsid inhibitor N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide. To Be Published
- Release Date
- 2022-10-05
- Peptides
- Capsid protein p24: ABCDEF
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
AC
AD
AE
AF
A